William S. Marth has been named chairman of the board at AMRI, a position that had been held by Thomas E. D’Ambra, Ph.D. since the company’s founding. AMRI’s board voted to separate the role of chairman and chief executive officer, and Dr. D’Ambra will retain his roles as a member of the board, president and chief executive officer. Mr. Marth joined the board in 2012.
 
Mr. Marth brings global experience in strategic planning, IR, R&D, supply chain and regulatory. He was formerly president and chief executive officer of Teva – Americas, and retired in 2012. He previously served as president and chief executive officer of Teva North America and prior to that as president and chief executive officer of Teva USA. He also served as executive vice president and vice president of sales and marketing for Teva USA. He was integral in Teva’s $6.8 billion Cephalon and $7.4 billion Barr Laboratories acquisitions. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.
 
Mr. Marth said, “AMRI maintains a unique and strong position providing a broad range of drug discovery, development and manufacturing services to the pharmaceutical, biotechnology and related industries. I have been impressed with the company’s accomplishments and potential and look forward to contributing to growing both the depth and breadth of AMRI’s services in my role as chairman.”
 
Dr. D’Ambra said, “Bill is an accomplished and visionary industry leader who has an unparalleled record of commercial success. Since joining the board approximately one year ago, he has been very helpful to me personally as well as to the company. I am confident with Bill as our chairman, that the company is poised for continued and greater success. I, along with the rest of the members of the board, look forward to continuing to serve with Bill on behalf of all AMRI shareholders.”